Sign in
BNTC Stock Price, Chart, Stats & News
Benitec Biopharma Inc.
Save
293.44M
Market cap
–
Current P/E
–
Forward P/E
BNTC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -11.87% |
Operating margin | -9090.65% |
Pretax margin | -8327.88% |
Net margin | -8327.88% |
Effective tax rate | – |
ROA | -24.28% |
ROE | -38.92% |
D/E | 0.01x |
Interest coverage ratio | – |
BNTC valuation
P/E | – |
P/S | 484.82x |
P/B | 2.52x |
P/CF | -25.19x |
P/FCF | -14.37x |
P/OCF | -25.19x |
PEG | -1.72x |
EV multiple | -8.91x |
About
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection.
Similar securities
Based on sector and market capitalization
Report issue